Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jun 22, 2023 10:40am
373 Views
Post# 35509071

RE:ONCY pelareorep selected for Phase 3 Pancreatic Cancer trial

RE:ONCY pelareorep selected for Phase 3 Pancreatic Cancer trialPanCAN’s Precision Promise Clinical Trial Consortium sites:

Baylor College of Medicine (Houston, TX)
Principal investigator: Benjamin Musher, MD

Cedars-Sinai Medical Center (Los Angeles, CA)
Principal investigator: Arsen Osipov, MD

Dana-Farber/Harvard Cancer Center (Boston, MA)
Principal investigator: Brian Wolpin, MD, MPH

Fred Hutch Cancer Center (Seattle, WA)
Principal investigator: Andrew Coveler, MD

Harold C. Simmons Comprehensive Cancer Center  (Dallas, TX)
Principal investigator: Herbert Zeh, MD

HonorHealth Research Institute (Scottsdale, AZ)
Principal investigator: Erkut Borazanci, MD
Opening Soon

Huntsman Cancer Institute at the University of Utah  (Salt Lake City, UT)
Principal investigator: Ignacio Garrido-Laguna, MD, PhD

Johns Hopkins Medicine (Baltimore, MD)
Principal Investigator: Daniel Laheru, MD

Mayo Clinic Cancer Center (Rochester, MN)
Principal investigator: Robert McWilliams, MD

Medical College of Wisconsin (Milwaukee, WI)
Principal investigator: Susan Tsai, MD, MHS, FACS

Memorial Sloan Kettering Cancer Center (New York City, NY)
Principal investigator: Anna Varghese, MD

Moores Cancer Center at UC San Diego Health (San Diego, CA)
Principal investigator: Aaron Miller, MD

Perelman School of Medicine University of Pennsylvania (Philadelphia, PA)
Principal investigator: Gregory Beatty, MD, PhD

Perlmutter Cancer Center/NYU Langone Health (New York City, NY)
Principal investigator: Diane Simeone, MD

Sylvester Comprehensive Cancer Center  (Miami, FL)
Principal investigator: Peter Hosein, MD

The University of Chicago (Chicago, IL)
Principal investigator: Hedy Kindler, MD

The University of Texas MD Anderson Cancer Center (Houston, TX)
Principal Investigator: Shubham Pant, MD

UC San Francisco Helen Diller Family Comprehensive Cancer Center (San Francisco, CA)
Principal investigator: Andrew Ko, MD

University of Cincinnati Cancer Center (Cincinnati, OH)
Principal investigator: Davendra Sohal, MD

University of Florida Health – Cancer Center (Gainesville, FL)
Principal investigator: Thomas George, MD, FACP

University of Michigan Rogel Cancer Center (Ann Arbor, MI)
Principal investigator: Vaibhav Sahai, MBBS, MS

University of Nebraska Medical Center (Omaha, NE)
Principal investigator: Kelsey Klute, MD
Opening Soon

University of New Mexico Comprehensive Cancer Center (Albuquerque, NM)
Principal investigator: Ursa Brown-Glaberman, MD

Vanderbilt University Medical Center (Nashville, TN)
Principal investigator: Dana Cardin, MD, MSCI
Opening Soon

Virginia Commonwealth University (Richmond, VA)
Principal investigator: Jose Trevino, MD, FACS

Virginia Mason Medical Center (Seattle, WA)
Principal investigator: Vincent Picozzi, MD

Washington University School of Medicine (St. Louis, MO)
Principal investigator: Kian-Huat Lim, MD, PhD

Weill Cornell Medicine (New York City, NY)
Principal investigator: Manuel Hidalgo, MD, PhD


https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-inc?postid=35508569

<< Previous
Bullboard Posts
Next >>